12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (TA1045)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 March 2025
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 August 2026
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)Product type:GuidanceProgramme:NICE guidelinePublished: 27 November 2024
Asthma pathway (BTS, NICE, SIGN) (NG244)Product type:GuidanceProgramme:NICE guidelinePublished: 27 November 2024
Benralizumab for treating severe eosinophilic asthma (TA565)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 September 2019Published: 6 March 2019
Budesonide–glycopyrronium–formoterol fumarate for treating severe asthma in people 12 years and over TS ID 12018Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital technologies for applying algorithms to spirometry to support asthma and COPD diagnosis in primary care and community diagnostic centres: early-use assessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: 2 April 2026
Digital technologies to support self-management of asthma: early value assessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: 30 April 2026
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating severe asthma with type 2 inflammation (TA751)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 December 2021
Mepolizumab for treating severe eosinophilic asthma (TA671)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 February 2021
MT684 Smart Peak Flow for monitoring asthmaStatus:Topic prioritisationProgramme:Medical technologies guidanceExpected publication date: TBC
Noninvasive Vagus Nerve Stimulation For reactive airway diseaseStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Reslizumab for treating severe eosinophilic asthma (TA479)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2017
Tezepelumab for treating severe asthma (TA880)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 April 2023